St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)

Completed · Phase 2/Phase 3

Conditions studied: Anxiety Disorders, Mental Health

In brief

This study will determine whether the herbal product St. John's wort is safe and effective in treating generalized social anxiety disorder (GSAD). Study hypothesis: Hypericum perforatum (St. John's wort) is more effective in treating GSAD than placebo.

Key facts

Study ID

NCT00118833

Run by

National Center for Complementary and Integrative Health (NCCIH)

People needed

56

Starts

2002-08-01

Expected to finish

2006-06-01

Last updated by the study team

2007-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of GSAD
• Brief Social Phobia Scale (BSPS) score of 20 or higher

You may not qualify if…

• Comorbid anxiety, depressive, or bipolar disorders
• Schizophrenia
• Cognitive impairment
• Substance abuse or dependence within 1 year prior to study entry
• Any unstable medical condition
• Clinically significant laboratory or electrocardiogram (EKG) abnormality
• Currently use psychotropic medications or may need psychotropic medication during the study
• Psychotherapy within 6 weeks prior to study entry
• Failed a previous trial of St. John's wort at doses of 1800 mg/day or greater
• Pregnancy or breastfeeding

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.